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Abstract
Background: Enterocutaneous fistulas (ECF) are debilitating and usually result following complex abdominal
surgery. While there is an association with inflammatory bowel disease (IBD), a large number of fistulas occur after
surgery not related to IBD. The consequences of ECF include short bowel syndrome and the need for long term
parenteral nutrition.
ECF can heal spontaneously and in the case of IBD can be cured by medical therapy in some instances. Those that
do not resolve spontaneously have to be cured by surgery which is complex and associated with a high morbidity.
It is not considered traditional treatment to use the same medical therapy as in IBD to cure ECF caused by other
conditions.
A small case series has reported three patients with persistent ECF not related to IBD to have healed following use
of Infliximab which is the treatment commonly used for ECF caused by IBD. Infliximab acts by inhibiting the
activity of the inflammatory cytokine TNF- alpha. It is not known if this cytokine is present in ECF tissue in the
absence of IBD.
The aim of this study is to demonstrate the presence of inflammatory markers in tissue surrounding non-IBD ECF
and in particular to quantify the presence of the cytokine TNF- alpha. We hypothesise that TNF - alpha levels are
raised in non-IBD ECF.
Methods/Design: Tissue and serum from ECF of IBD and non-IBD patients will be prospectively collected at St.
Mark’s Hospital Intestinal Failure Unit. The control group will consist of patients undergoing colonoscopy for bowel
cancer screening, with normal findings. Biopsies of the terminal ileum will be obtained from this group during
colonoscopy. The fistula tract and serum cytokine profiles of interleukins (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10,
TNF- alpha, IFN-y, MCP-1, EGF and VEGF will be assessed.
Discussion: This study aims to assess the presence or absence of TNF- alpha expression in the ECF tissue in
non-IBD origin. If our hypothesis is correct we would then be able to study the use of the TNF- alpha inhibitor
Infliximab as a therapeutic option in the treatment of non-IBD ECF. Secondary aims include assessing the spectrum
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Background
Enterocutaneous fistulas (ECF) are abnormal communi-
cations between the gastrointestinal tract and the skin.
Although rare, they are associated with considerable
morbidity and mortality. Death related to ECF remains
disproportionately high when compared with other sur-
gical conditions. Mortality rates for ECF vary from 6 -
33% [1-5].
The incidence and aetiology of fistula are highly
dependent on the surgical experience and case load at
particular institutions and on patient and disease related
cofactors. Much of the published data relate to experi-
ence at specialised centres treating complex cases in
particularly unstable patients[6]. St. Mark’s Hospital is a
national and international referral centre for intestinal
and colorectal disorders. It is one of two national intest-
inal failure centres in England. The Intestinal Failure
Unit has a long standing interest in inflammatory bowel
disease (IBD), and this is reflected in the high preva-
lence of IBD patients treated. A recently completed
audit has revealed 177 patients with enterocutaneous fis-
tulas managed at St. Mark’s Hospital over 8 years (Janu-
ary 2003 to June 2010). Inflammatory bowel disease was
present in 85 (48.0%) patients. Of these, 69 patients had
Crohn’s disease and 16 ulcerative colitis.
It is estimated that 75-85% of ECF that form after an
operation occurs as a result of bowel injury or anasto-
motic leakage[1,7]. Fistula formation is usually asso-
ciated with surgery in the presence of IBD, malignancy
or with division of dense adhesions[1,7]. In the remain-
ing 15-25% of cases, ECF form spontaneously secondary
to the underlying pathology, with the most occurring in
those with Crohn’s disease[1,7].
Fistula formation can result in a number of serious or
debilitating complications, varying from disturbance of
fluid and electrolyte balance to sepsis and even death.
The patient will almost always suffer from severe dis-
comfort and pain. They may also have psychological
problems, including anxiety over the course of their dis-
ease, and a poor body image due to the malodorous
drainage fluid. Post-operative fistula formation often
results in prolonged hospitalisation, patient disability,
and enormous cost. Therapy has improved over time
with the introduction of parental nutrition, intensive
post-operative care, and advanced surgical techniques,
which has reduced mortality rates[8].
Although ECF can close spontaneously, those that
remain open after 2 months, surgical intervention is
likely to be needed as spontaneous closure is unlikely
after this interval [1,9]. It should be noted that major
abdominal surgery stimulates the formation of dense
adhesions. This reaction is most severe between 3 weeks
and 3 months after an operation, and further surgery
during this time is more likely to be complicated by fis-
tula recurrence [1,10,11].
The local production of tumour necrosis factor alpha
(TNF-a) is thought to have a key role in the initiation
and propagation of Crohn’s disease. Production of TNF-
a in the intestinal mucosa, serum and stool is increased
in patients with Crohn’s disease[12].
There are numerous biological activities that are
attributed to TNF-a activation. Some of these include
induction of the pro inflammatory cytokines such as IL-
1, IL-6 and enhancement of leukocyte movement or
migration from the blood vessels into the tissues by
increasing the permeability of the endothelial layer of
blood vessels.
In animal models, antibodies to TNF-a prevent or
reduce inflammation[13-17], suggesting that therapy
with such antibodies may be useful for chronic inflam-
matory disorders[18].
Infliximab has been approved for treating ankylosing
spondylitis, Crohn’s disease, fistulising Crohn’s disease,
psoriatic arthritis, psoriasis, rheumatoid arthritis, and
Ulcerative colitis. It has also been used in the treatment of
Behçet’s disease [19] and sciatica due to slipped discs[20].
Infliximab is a genetically constructed IgG1 murine -
human chimeric monoclonal anti TNF antibody that inhi-
bits a broad range of biological activities of TNF-a, poten-
tially by blocking the interaction of TNF-a with its
receptors, or causing lysis of cells that produce TNF-a [12].
Infliximab was first used for closure of fistulae in
Crohn’s disease in 1999. In a phase II clinical trial with
94 patients who had draining abdominal or perianal fis-
tula, the researchers showed that Infliximab was effec-
tive in closing fistula in 56-68% of patients[12].
A Phase III clinical trial (ACCENT 2) showed that
infliximab was additionally beneficial in maintaining clo-
sure of fistula, with almost two-thirds of all patients
treated with the 3 initial doses of infliximab having a fis-
tula response after 14 weeks, and 36% of patients main-
taining closure of fistula after a year, compared with
19% who received placebo therapy [21].
It is likely that persistent inflammation prevents ade-
quate healing of these fistulas and that TNF-a and the
subsequent stimulation of the pro-inflammatory cascade
promotes their existence.
Infliximab is currently not indicated for ECF caused
by conditions other than IBD. A recent small case series
of three patients has reported healing of persistent ECF
not associated with IBD to have healed following a sin-
gle infusion of infliximab[22]. There are no other studies
to support this series in the use of infliximab for non-
IBD ECF. The inflammatory activity of non-IBD ECF
has not been assessed in the past and the level of TNF-
a activity in these cases is not known.
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There is also no study of association of TNF-a with
Dendritic cells (DC). DC are potent antigen presenting
cells that bridge the adaptive and innate immune sys-
tems to induce and regulate immune responses. They
present as ‘immature’ cells specialised for antigen
uptake in most tissues of the body, particularly at sites
of interface with the external environment such as the
skin and mucosae and ECF. A property that distin-
guishes DC from other types of antigen presenting cell
is their potency in activating naïve T cells, which inter-
action generally occurs in secondary lymphoid tissue.
Upon activation DC produce pro-inflammatory cyto-
kines such as IL-12, IL-6 and TNF-a. They also up-
regulate and imprint homing markers such as cuta-
neous leukocyte antigen (CLA), also known as skin
homing marker and b7, a gut homing marker, on T
cells [23].
Hypothesis
Immunological factors and their interaction are in
operation within non-IBD ECF. The level of TNF-a
activity is similar in non-IBD ECF and IBD ECF but ele-
vated when compared with control small bowel.
Aim
The aim of this study is to assess the inflammatory
activity, with a particular emphasis on TNF-a of non-
IBD ECF when compared with IBD ECF and control
small bowel. If this study can show the presence of
TNF-a in the fistula tract then there would be a poten-
tial for a novel therapy for patients with persistent ECF
not associated with IBD. This would be an alternative
option and benefit an already surgically challenging
group of patients associated with a high morbidity and
mortality where it is deemed conservative management
has failed.
We will assess prospectively immunological factors
involved in the pathogenesis in non-IBD ECF. We will
compare immunological factors in three groups of
patients;
• Group (i) non-inflammatory bowel disease ECF
• Group (ii) inflammatory bowel disease ECF
• Group (iii) normal bowel mucosa (control group)
Methods/Design
Inclusion criteria
For Group (i) non-inflammatory bowel disease ECF:
• Consent to the study
• Male or Female
• 18+ years
• Single or multiple ECF for at least 3 months dura-
tion as a result of non-inflammatory bowel disease, and
not responding to standard treatments.
• ECF confirmed to be due to non-inflammatory
bowel disease by radiography, endoscopy or pathological
examination.
For Group (ii) inflammatory bowel disease ECF:
• Consent to the study
• Male or Female
• 18+ years
• Single or multiple ECF for at least 3 months dura-
tion as a result of inflammatory bowel disease and not
responding to standard treatments.
• ECF confirmed to be due to inflammatory bowel dis-
ease by radiography, endoscopy or pathological
examination.
• Patients with stable inflammatory bowel disease.
For Group (iii) normal bowel mucosa (control group):
• Consent to the study
• Male or Female
• 18+ years
• Healthy volunteers
• Normal endoscopic examination of the bowel
• No prior history of inflammatory bowel disease or
ECF
Exclusion criteria
For Group (i) and Group (iii):
• Current sepsis or abscess
• Previous treatment with infliximab, investigational
agents or any medication which reduces the concentra-
tion of TNF- a
• History of Crohn’s disease or Ulcerative Colitis
• Pregnancy
For Group (ii):
• Current sepsis or abscess
• Previous treatment with infliximab, investigational
agents or any medication which reduces the concentra-
tion of TNF- a
• Patients taking steroids for inflammatory bowel dis-
ease within 1 month prior to start of the study.




An eligible patient will be detected at referral, seen in
the outpatient clinic or ward and offered participation
in this study. The study will be explained, discussed and
patients encouraged to ask questions for discussion. A
patient information sheet will be provided. Informed
consent will be obtained for the study by the Good Clin-
ical Practice (GCP) trained clinical research fellow or
principal investigator. Patients, who decline to enter the
study, will be treated with the normal standard of clini-
cal care provided.
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For patients who enter the study:
The number and location of the ECF will be noted.
Drawings as well as photographs will be used to docu-
ment the sites of disease.
At the time of operation or on the ward or in outpati-
ents, biopsies will be taken under local anaesthetic from
the ECF tracts of non-IBD and IBD patients. Groups (i)
and (ii).
A biopsy of the ECF tract will be taken to assess for
baseline pro and anti-inflammatory cytokine markers
including TNF-a level. Biopsy forceps will be used to
take tissue samples under direct vision from the fistula
tract. We will only take five 2 mm samples.
Healthy patients undergoing screening colonoscopy or
sigmoidoscopy with normal mucosa endoscopically and
histologically will be used as controls. A maximum of
ten biopsies will be taken from the colon or small intes-
tine in addition to those required for clinical evaluation.
Group (iii).
Peripheral blood (2-50 ml) will be obtained, taken by a
clinician or other GCP trained person from all three
groups. Groups (i), (ii) and (iii).
Data will be acquired on a FACS Calibur cytometer
(BD Biosciences) and analysed using Win List 5.0 soft-
ware (Verity, ME, US). Data generated will be analysed
by the clinical research fellow, principal investigator and
statistician at St. Mark’s Hospital.
Primary outcome measure
Cytokine profiles in the mucosa from all three groups
will be assessed using multiplex bead analysis. Cytokine
blood tests machine analyser will be used to simulta-
neously analyse the following cytokines, chemokine’s
and growth factors: IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8,
IL-10, TNF- a, IFN-y, MCP-1, EGF and VEGF.
Secondary outcome measures
Using flow cytometer technique, we will identify
whether the homing markers CLA and b7 are
expressed on blood T cells and DC in the three
groups. In addition, the production of the pro-inflam-
matory cytokines; TNF- a, IL-12, IL-17A and IFN- y
in DC from blood and tissue in these group will be
determined.
Sample size justification
The study was powered to determine a 60% increase in
TNF-a expression between non-IBD ECF and the con-
trol group. With a 5% significance level and 90% power,
14 patients will be required in each group.
Statistical analyses will be carried out using Sigma Stat
software (SPSS Inc., Chicago, IL, USA). Pooled data
from each group will be expressed as median values ±
standard error (s.e.). Two-tailed t-tests will be employed
to compare normally distributed data and Mann-Whit-
ney rank-sum tests will be used to analyse non-normally
distributed data. Values of P < 0•05 will be considered
significant.
Safety and Monitoring
There is potential for increased pain and discomfort
from the blood tests and biopsies of the fistula tract. In
both cases the patient will be informed during the initial
explanation, consent stage, and prior to the procedure,
that they may feel a very ‘small pinch or prick’ sensation
as the blood test or biopsy is being performed. There is
minimal risk of very light bleeding following either test,
and this would be controlled as is in normal standard
clinical practice with the application of gentle pressure
until any bleeding subsides.
There is a small risk of an infection occurring at the
site of blood taking and this will be minimised by the
use of standard hospital guidelines in relation to use of
alcohol hand gel and sterile technique as is part of nor-
mal standard clinical care.
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